News Releases

Dec 09, 2019
Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia
First three patients experienced prompt hematopoietic reconstitution, and no clonal hematopoiesis Early first-in-human data provide insights into relationship between product specific characteristics, including cell dose, editing efficiency, and fetal hemoglobin induction Additional study results
Additional Formats
Dec 07, 2019
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
- The first two patients treated with the 3e13 vg/kg dose achieved stable Factor VIII (FVIII) levels demonstrating durability in the normal range through 44 and 37 weeks, respectively - All five patients in the 3e13 vg/kg dose cohort achieved normal range FVIII levels within 5-7 weeks following
Additional Formats
Nov 26, 2019
Sangamo Therapeutics Appoints James R. Meyers to Its Board of Directors
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 26, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of James R. Meyers , an accomplished pharmaceutical executive with three decades of commercial experience, to the Company's Board of Directors.
Additional Formats
Nov 08, 2019
Sangamo Therapeutics Announces New Scientific Advisory Board
Members include distinguished international experts across a diverse range of scientific and therapeutic areas BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 8, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory
Additional Formats
Nov 06, 2019
Sangamo Therapeutics Reports Third Quarter 2019 Financial Results
Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported third quarter 2019 financial results and recent business highlights.
Additional Formats
Displaying 1 - 10 of 47